Enhancing antidepressant bioavailability and CNS targeting using cyclodextrin-enabled drug delivery systems

Abstract

Drug delivery methods based on cyclodextrin (CD) offer a viable way to improve antidepressant medication by addressing problems including poor solubility and limited bioavailability. This review emphasizes how complexing different antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), with β-CD or derivatives enhances pharmacokinetics, decreases systemic toxicity, and improves drug solubility and stability. CD formulations improve therapeutic efficacy and allow for sustained or targeted drug release, according to analysis of in vitro and in vivo investigations. CD-based platforms are noteworthy for their cost-effectiveness, biocompatibility, and ease of formulation when compared to other delivery methods, notwithstanding difficulties with drug-loading capacity. In order to confirm the clinical benefits of CD-antidepressant complexes, particularly in treatment-resistant instances, the study calls for additional in vivo research. It recommends investigating hybrid solutions to address constraints and optimize advantages. In the end, including CDs into antidepressant therapies may result in more individualized depression interventions and improved therapeutic effects.